CellCentric Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cellcentric.com
Clinical Trials
6
Active:4
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 2
1 (16.7%)Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1
Recruiting
- Conditions
- Non Hodgkin LymphomaHaematological MalignancyAcute Myeloid LeukemiaHigher-risk Myelodysplastic SyndromeMultiple MyelomaPeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04068597
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇺🇸The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland, United States
Study to Evaluate CCS1477 in Advanced Tumours
Phase 1
Active, not recruiting
- Conditions
- Metastatic Castration-Resistant Prostate CancerNon-small Cell Lung CancerMetastatic Breast CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇫🇷Institute Bergonie, Bordeaux, France
News
No news found